In Vivo Evaluation of Lenvatinib's Anti-Tumor Effects

The animal experiments were approved by the Institutional Animal Care and Use Committee of The Fifth Medical Center (former name: The 302nd Hospital of Chinese PLA), General Hospital of Chinese People's Liberation Army (the ID of certification: IACUC‐2019‐001, Figure S1). All the animal studies were conducted in accordance with the UK Animals (Scientific Procedures) Act of 1986 and the associated guidelines. AML cells or MHCC97‐H cells were cultured and resuspended in physiological saline. Next, cell suspensions or cell suspensions containing 2% Poloxamer 407 were subcutaneously injected into nude mice. The concentration of cells in the cell suspension was 10⁷ cells/mL. About 0.2 mL cell suspension per site was injected subcutaneously into nude mice at various sites. Three to four days’ after injection, the mice received 1, 0.5, 0.2 or 0.1 mg/kg lenvatinib by oral administration. The mice received lenvatinib treatment once per 2 days. After 10 treatments (about 20‐21 days), the mice were harvested and the volumes or weights of subcutaneous tumor tissues were examined. The tumor volumes of subcutaneous tumor tissues were calculated as tumor length × tumor width × tumor width/2.13, 14 The inhibition rates of lenvatinib on the subcutaneous growth of AML cells were calculated as [(control group tumor volumes)−(lenvatinib group tumor volumes)]/(control group tumor volumes) × 100%; [(control group tumor weights)−(lenvatinib group tumor weights)]/(control group tumor weights) × 100%.